clinical trial · NCT07076407
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Major Depressive DisorderAzetukalnerPlacebo
brief summary
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
started
Jul 8, 2025
primary completion
May 1, 2027
completion
Jul 1, 2027
last updated
Apr 8, 2026
official title
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate Azetukalner in Moderate-to-Severe Major Depressive Disorder
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol